Perspective Therapeutics, Inc. - 8-K Filing
Perspective Therapeutics reports Q3 2026 net loss of $32.4 million and announces $202 million in cash reserves. (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CATX